Price D., Fletcher M., van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009. https://doi.org/10.1038/npjpcrm.2014.9..
DOI: 10.1038/npjpcrm.2014.9

Архипов В.В., Айсанов З.Р., Авдеев С.Н. Эффективность комбинаций ингаляционных глюкокортикостероидов и длительно действующих β-агонистов в условиях реальной медицинской практики: результаты многоцентрового кросс-секционного исследования у российских пациентов с бронхиальной астмой. Пульмонология. 2021;(5):613–626. https://doi.org/10.18093/0869-0189-2021-31-5-613-626..
DOI: 10.18093/0869-0189-2021-31-5-613-626

Shams M.R., Fineman S.M. Asthma adherence: how can we help our patients do it better? Ann Allergy Asthma Immunol. 2014;112(1):9–12. https://doi.org/10.1016/j.anai.2013.10.013..
DOI: 10.1016/j.anai.2013.10.013

Coleman C., Limone B., Sobieraj D., Lee S., Roberts M., Kaur R., Alam T. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527–539. https://doi.org/10.18553/jmcp.2012.18.7.527..
DOI: 10.18553/jmcp.2012.18.7.527

Tamura G., Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med. 2007;101(9):1895–1902. https://doi.org/10.1016/j.rmed.2007.05.001..
DOI: 10.1016/j.rmed.2007.05.001

Lindsay J., Heaney L.G. Non-adherence in difficult asthma and advances in detection. Expert Rev Respir Med. 2013;7(6):607–614. https://doi.org/10.1586/17476348.2013.842129..
DOI: 10.1586/17476348.2013.842129

Price D., Robertson A., Bullen K., Rand C., Horne R., Staudinger H. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med. 2010;10:1. https://doi.org/10.1186/1471-2466-10-1..
DOI: 10.1186/1471-2466-10-1

Ward C., Pais M., Bish R., Reid D., Feltis B., Johns D., Walters E.H. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax. 2002;57(4):309–316. https://doi.org/10.1136/thorax.57.4.309..
DOI: 10.1136/thorax.57.4.309

Hochhaus G. Relative receptor affinity comparisons among inhaled/intranasal corticosteroids: perspectives on clinical relevance. Respir Res. 2008;9(1):75. https://doi.org/10.1186/1465-9921-9-75..
DOI: 10.1186/1465-9921-9-75

Bateman E., Bleecker E., Lotvall J., Woodcock A., Forth R., Medley H. et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med. 2012;106(5):642–650. https://doi.org/10.1016/j.rmed.2012.01.004..
DOI: 10.1016/j.rmed.2012.01.004

Woodcock A., Bateman E., Busse W., Lotvall J., Snowise N., Forth R. et al. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respir Res. 2011;12(1):132. https://doi.org/10.1186/1465-9921-12-132..
DOI: 10.1186/1465-9921-12-132

Woodcock A., Bleecker E., Busse W., Lotvall J., Snowise N., Frith L. et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res. 2011;12(1):160. https://doi.org/10.1186/1465-9921-12-160..
DOI: 10.1186/1465-9921-12-160

Busse W., Bleecker E., Bateman E., Lotvall J., Forth R., Davis A. et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomized, placebo-controlled trial. Thorax. 2012;67(1):35–41. https://doi.org/10.1136/thoraxjnl-2011-200308..
DOI: 10.1136/thoraxjnl-2011-200308

Medley H., Orozco S., Allen A. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. Clin Ther. 2012;34(8):1683–1695. https://doi.org/10.1016/j.clinthera.2012.06.024..
DOI: 10.1016/j.clinthera.2012.06.024

Lotvall J., Bleecker E., Busse W., O’Byrne P., Woodcock A., Kerwin E. et al. Efficacy and safety of fluticasone furoate 100 µg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomized trial. Respir Med. 2014;108(1):41–49. https://doi.org/10.1016/j.rmed.2013.11.009..
DOI: 10.1016/j.rmed.2013.11.009

Woodcock A., Lotvall J., Busse W., Bateman E., Stone S., Ellsworth A., Jacques L. Efficacy and safety of fluticasone furoate 100 mcg and 200 mcg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomized study. BMC Pulm Med. 2014;14:113. https://doi.org/10.1186/1471-2466-14-113..
DOI: 10.1186/1471-2466-14-113

Busse W.W., Bateman E.D., O’Byrne P.M., Lötvall J., Woodcock A., Medley H. et al. Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial. Allergy. 2014;69(11):1522–1530. https://doi.org/10.1111/all.12480..
DOI: 10.1111/all.12480

O’Byrne P.M., Woodcock A., Bleecker E.R., Bateman E.D., Lötvall J., Forth R. et al. Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. Respir Res. 2014;15(1):88. https://doi.org/10.1186/s12931-014-0088-z..
DOI: 10.1186/s12931-014-0088-z

Feehan M., Ranker L., Durante R., Cooper D., Jones G., Young D., Munger M.A. Adherence to controller asthma medications: 6-month prevalence across an US community pharmacy chain. J Clin Pharm Ther. 2015;40(5):590–593. https://doi.org/10.1111/jcpt.12316..
DOI: 10.1111/jcpt.12316

Albertson T.E., Richards J.R., Zeki A.A. The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience. Ther Adv Respir Dis. 2016;10(1):43–56. https://doi.org/10.1177/1753465815619136..
DOI: 10.1177/1753465815619136

Kempsford R., Norris V., Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013;26(2):256–264. https://doi.org/10.1016/j.pupt.2012.12.001..
DOI: 10.1016/j.pupt.2012.12.001

Lötvall J., Bateman E.D., Bleecker E.R., Busse W.W., Woodcock A., Follows R. et al. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur Respir J. 2012;40(3):570–579. https://doi.org/10.1183/09031936.00121411..
DOI: 10.1183/09031936.00121411

Sterling R., Lim J., Frith L., Snowise N.G., Jacques L., Haumann B. Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial. Respir Med. 2012;106(8):1110–1115. https://doi.org/10.1016/j.rmed.2012.03.007..
DOI: 10.1016/j.rmed.2012.03.007

Lötvall J., Bateman E.D., Busse W.W., O’Byrne P.M., Woodcock A., Toler W.T. et al. Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. J Negat Results Biomed. 2014;13(1):9. https://doi.org/10.1186/1477-5751-13-9..
DOI: 10.1186/1477-5751-13-9

Oliver A., VanBuren S., Allen A., Hamilton M., Tombs L., Kempsford R., Qaqundah P. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5–11 Years with Persistent Asthma: A Randomized Trial. Clin Pharmacol Drug Dev. 2014;3(3):215–221. https://doi.org/10.1002/cpdd.92..
DOI: 10.1002/cpdd.92

Ni Chroinin M., Greenstone I., Lasserson T., Ducharme F. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev. 2009;(4):CD005307. https://doi.org/10.1002/14651858.CD005307.pub2..
DOI: 10.1002/14651858.CD005307.pub2

Chen X., Zheng X., Jiang J., Hu P., Wu K., Zhuang L. et al. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects. Pharmacotherapy. 2015;35(6):586–599. https://doi.org/10.1002/phar.1598..
DOI: 10.1002/phar.1598

Nakahara N., Wakamatsu A., Kempsford R., Allen A., Yamada M., Nohda S., Hirama T. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. Int J Clin Pharmacol Ther. 2013;51(8):660–671. https://doi.org/10.5414/CP201822..
DOI: 10.5414/CP201822

Kempsford R., Allen A., Bal J., Rubin D., Tombs L. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Br J Clin Pharmacol. 2013;75(6):1478–1487. https://doi.org/10.1111/bcp.12019..
DOI: 10.1111/bcp.12019

Allen A., Davis A., Hardes K., Tombs L., Kempsford R. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination. Clin Ther. 2012;34(12):2316–2332. https://doi.org/10.1016/j.clinthera.2012.11.001..
DOI: 10.1016/j.clinthera.2012.11.001

Oliver A., Bjermer L., Quinn D., Saggu P., Thomas P., Yarnall K., Lötvall J. Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy. 2013;68(9):1136–1142. https://doi.org/10.1111/all.12205..
DOI: 10.1111/all.12205

Komase Y., Asako A., Kobayashi A., Sharma R. Ease-of-use preference for the ELLIPTA(R) dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naive Japanese volunteers aged 40 years or older. Int J Chron Obstruct Pulmon Dis. 2014;9:1365–1375. https://doi.org/10.2147/COPD.S72762..
DOI: 10.2147/COPD.S72762

Svedsater H., Dale P., Garrill K., Walker R., Woepse M.W. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013;13:72. https://doi.org/10.1186/1471-2466-13-72..
DOI: 10.1186/1471-2466-13-72

Oliver A., Quinn D., Goldfrad C., van Hecke B., Ayer J., Boyce M. Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial. Clin Transl Allergy. 2012;2(1):11. https://doi.org/10.1186/2045-7022-2-11..
DOI: 10.1186/2045-7022-2-11

Busse W., O’Byrne P., Bleecker E., Lotvall J., Woodcock A., Andersen L. et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomized trial. Thorax. 2013;68(6):513–520. https://doi.org/10.1136/thoraxjnl-2012-202606..
DOI: 10.1136/thoraxjnl-2012-202606

Woodcock A., Bleecker E., Lotvall J., O’Byrne P., Bateman E., Medley H. et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest. 2013;144(4):1222–1229. https://doi.org/10.1378/chest.13-0178..
DOI: 10.1378/chest.13-0178

Kempsford R., Oliver A., Bal J., Tombs L., Quinn D. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respir Med. 2013;107(12):1873–1880. https://doi.org/10.1016/j.rmed.2013.07.002..
DOI: 10.1016/j.rmed.2013.07.002

O’Byrne P., Bleecker E., Bateman E., Busse W., Woodcock A., Forth R. et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J. 2014;43(3):773–782. https://doi.org/10.1183/09031936.00064513..
DOI: 10.1183/09031936.00064513

Bateman E., O’Byrne P., Busse W., Lotvall J., Bleecker E., Andersen L. et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014; 69(4):312–319. https://doi.org/10.1136/thoraxjnl-2013-203600..
DOI: 10.1136/thoraxjnl-2013-203600

Oliver A., Vanburen S., Allen A., Hamilton M., Tombs L., Inamdar A. et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clin Ther. 2014;36(6):928–939.e1. https://doi.org/10.1016/j.clinthera.2014.03.014..
DOI: 10.1016/j.clinthera.2014.03.014

Bleecker E., Lotvall J., O’Byrne P., Woodcock A., Busse W., Kerwin E. et al. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. J Allergy Clin Immunol Pract. 2014;2(5):553–561. https://doi.org/10.1016/j.jaip.2014.02.010..
DOI: 10.1016/j.jaip.2014.02.010

Lin J., Kang J., Lee S., Wang C., Zhou X., Crawford J. et al. Fluticasone furoate/vilanterol 200/25 mcg in asian asthma patients: a randomized trial. Respir Med. 2015;109(1):44–53. https://doi.org/10.1016/j.rmed.2014.10.012..
DOI: 10.1016/j.rmed.2014.10.012

Bernstein D., Bateman E., Woodcock A., Toler W., Forth R., Jacques L. et al. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. J Asthma. 2015;52(10):1073–1083. https://doi.org/10.3109/02770903.2015.1056350..
DOI: 10.3109/02770903.2015.1056350

van der Palen J., Thomas M., Chrystyn H., Sharma R.K., van der Valk P.D., Goosens M. et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2016;26:16079. https://doi.org/10.1038/npjpcrm.2016.79..
DOI: 10.1038/npjpcrm.2016.79

Woodcock A., Vestbo J., Bakerly N.D., New J., Gibson J.M., McCorkindale S. et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clin ical practice: an openlabel, parallel group, randomised controlled trial. Lancet. 2017;390(10109):2247–2255. https://doi.org/10.1016/S0140-6736(17)32397-8..
DOI: 10.1016/S0140-6736(17)32397-8